BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31367864)

  • 1. Telmisartan attenuates N-nitrosodiethylamine-induced hepatocellular carcinoma in mice by modulating the NF-κB-TAK1-ERK1/2 axis in the context of PPARγ agonistic activity.
    Saber S; Khodir AE; Soliman WE; Salama MM; Abdo WS; Elsaeed B; Nader K; Abdelnasser A; Megahed N; Basuony M; Shawky A; Mahmoud M; Medhat R; Eldin AS
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1591-1604. PubMed ID: 31367864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
    Saber S; Mahmoud AAA; Goda R; Helal NS; El-Ahwany E; Abdelghany RH
    Toxicol Lett; 2018 Oct; 295():32-40. PubMed ID: 29859236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma.
    Younis NS; Ghanim AMH; Saber S
    Sci Rep; 2019 Dec; 9(1):19095. PubMed ID: 31836811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan ameliorates dextran sodium sulfate-induced colitis in rats by modulating NF-κB signalling in the context of PPARγ agonistic activity.
    Saber S; Basuony M; Eldin AS
    Arch Biochem Biophys; 2019 Aug; 671():185-195. PubMed ID: 31326516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactosylated Chitosan Nanoparticles Potentiate the Anticancer Effects of Telmisartan In Vitro and in a
    Nasr M; Kira AY; Saber S; Essa EA; El-Gizawy SA
    Mol Pharm; 2023 Sep; 20(9):4758-4769. PubMed ID: 37585079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma.
    Sun BS; Dong QZ; Ye QH; Sun HJ; Jia HL; Zhu XQ; Liu DY; Chen J; Xue Q; Zhou HJ; Ren N; Qin LX
    Hepatology; 2008 Dec; 48(6):1834-42. PubMed ID: 18972404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression.
    Cao LQ; Shao ZL; Liang HH; Zhang DW; Yang XW; Jiang XF; Xue P
    Cancer Lett; 2015 Apr; 359(1):127-35. PubMed ID: 25592041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation.
    Arsura M; Panta GR; Bilyeu JD; Cavin LG; Sovak MA; Oliver AA; Factor V; Heuchel R; Mercurio F; Thorgeirsson SS; Sonenshein GE
    Oncogene; 2003 Jan; 22(3):412-25. PubMed ID: 12545162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1.
    Yang L; Inokuchi S; Roh YS; Song J; Loomba R; Park EJ; Seki E
    Gastroenterology; 2013 May; 144(5):1042-1054.e4. PubMed ID: 23391818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
    Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of matrix stiffness relating integrin β1 signaling pathway inhibits tumor growth in vitro and in hepatocellular cancer xenografts.
    Wang C; Jiang X; Huang B; Zhou W; Cui X; Zheng C; Liu F; Bi J; Zhang Y; Luo H; Yuan L; Yang J; Yu Y
    BMC Cancer; 2021 Nov; 21(1):1276. PubMed ID: 34823500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemopreventive and antitumor effects of benzyl isothiocynate on HCC models: A possible role of HGF /pAkt/ STAT3 axis and VEGF.
    Zakaria S; Helmy MW; Salahuddin A; Omran G
    Biomed Pharmacother; 2018 Dec; 108():65-75. PubMed ID: 30216802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Nasr M; Selima E; Hamed O; Kazem A
    Eur J Pharmacol; 2014 Jan; 723():267-75. PubMed ID: 24291100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARγ.
    Han M; Gao H; Ju P; Gao MQ; Yuan YP; Chen XH; Liu KL; Han YT; Han ZW
    Biomed Pharmacother; 2018 Jul; 103():272-283. PubMed ID: 29656183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor.
    Zhou L; Wang DS; Li QJ; Sun W; Zhang Y; Dou KF
    Oncol Rep; 2012 Sep; 28(3):874-82. PubMed ID: 22736202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
    Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA
    Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways.
    Abd-Elbaset M; Mansour AM; Ahmed OM; Abo-Youssef AM
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1611-1624. PubMed ID: 32270258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.
    Ozaki I; Zhang H; Mizuta T; Ide Y; Eguchi Y; Yasutake T; Sakamaki T; Pestell RG; Yamamoto K
    Clin Cancer Res; 2007 Apr; 13(7):2236-45. PubMed ID: 17404108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wogonin inhibits cell cycle progression by activating the glycogen synthase kinase-3 beta in hepatocellular carcinoma.
    Hong M; Almutairi MM; Li S; Li J
    Phytomedicine; 2020 Mar; 68():153174. PubMed ID: 31991293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.